The FDA will host talks on COVID-19 booster doses and children’s immunizations.
Three committee meetings on COVID-19 booster doses and vaccines for children will be held by the Food and Drug Administration this month.
Two advisory committee meetings on the Jannsen and Moderna COVID-19 vaccine boosters, as well as one on Pfizer’s anticipated request to revise its emergency use permission request to allow use of its COVID-19 vaccine on children aged 5-11.
The first two booster shot meetings will be held on October 14 and 15.
The committee will also hear a presentation from the National Institute of Health on the safety and efficacy of receiving initial doses of one COVID-19 vaccine and then a booster dose of another manufacturer’s shot during the second meeting.
On Sept. 22, the FDA approved the Pfizer-BioNTech COVID-19 booster dose for those aged 65 and up, those who are at high risk of severe COVID-19, and those who are exposed to it often in institutions or at work.
In the first week of eligibility, approximately 2 million Americans received booster doses, according to White House Coronavirus Response Team Coordinator Jeff Zients.
Pfizer’s anticipated request will be discussed at the third meeting on Oct. 26.
In a statement, FDA acting commissioner Janet Woodcock said, “We know from our vast experience with our pediatric vaccines that children are not small adults, and we will conduct a comprehensive evaluation of clinical trial data submitted in support of the vaccine’s safety and effectiveness in a younger pediatric population.”
The announcement comes as the country approaches the sad milestone of 700,000 COVID-19 deaths since the pandemic began on Friday, raising concerns about how the country would fare as the winter months approach.
At nokiamobilephonenews.co.uk, Nokia News provides an independent, constantly updated stream of breaking news from the United States and throughout the world.